Mohammed Al Edreesi, Gilles Caillé, Claire Dupuis, Yves Théoret, Khazal Paradis – 1 November 1995 – Thirty‐two children who had undergone liver transplantation were paired according to their post‐transplantation duration, renal function, and diagnoses when possible and randomized either to continue nifedipine (NIF group) or switch to diltiazem (DIL group), in addition to continuing their usual immunosuppressive medications.

Giovanna Fattovich, Graham McIntyre, Mark Thursz, Kathryn Colman, Giustina Giuliano, Alfredo Alberti, Howard C. Thomas, William F. Carman – 1 November 1995 – Precore/core genes from hepatitis B e antigen (HBeAg)‐positive and antibody to HBeAg (anti‐HBe) positive individuals with active hepatitis have been analyzed to search for correlations with response to interferon before and after treatment. Pretreatment, no precore stop codon mutants were detected, even at the 3% level, in HBeAg‐positive responders or nonresponders.

Koichi Tsuneyama, Judy van de Water, David van Thiel, Ross Coppel, Boris Ruebner, Yasuni Nakanuma, E. Rolland Dickson, M. Eric Gershwin – 1 November 1995 – The presence of antimitochondrial antibodies (AMA) is a major criterion for the diagnosis of primary biliary cirrhosis (PBC). Although it is not clear that AMA are involved in the pathogenesis of the disease, the study of these autoantibodies has enabled much information to be accumulated about the specificity of this response.

Shinichi Kiso, Sumio Kawata, Shinji Tamura, Shigeki Higashiyama, Nobuyuki Ito, Hirofumi Tsushima, Naoyuki Taniguchi, Yuji Matsuzawa – 1 November 1995 – Several growth factors including hepatocyte growth factor (HGF) have been implicated in the regulation of liver regeneration. Recently, we reported that heparinbinding epidermal growth factor (EGF)‐like growth factor (HB‐EGF) has hepatotrophic effects in vitro. We investigated the role of HB‐EGF as a hepatotrophic factor in regenerating rat liver after 70% partial hepatectomy.

David H. van Thiel – 1 November 1995

Philip Rosenthal, Luis Podesta, Robert Grier, Jonathan W. Said, Linda Sher, Jose Cocjin, Frederick Watanabe, Eric Vasiliauskas, Robert Van De Velde, Leonard Makowka – 1 November 1995 – Orthotopic liver transplantation has been used to treat glycogen storage disease type IV. Most long‐term surviving patients who have undergone liver transplantation have been free of neuromuscular and cardiac morbidity, and regression of cardiac amylopectin infiltration has been reported after liver transplantation. Leukocyte inclusions in glycogen storage disease type IV have also been reported.

Cornel C. Sieber – 1 November 1995 – Background/Aims: Because the vasodilator nitric oxide is overproduced in cirrhosis, this substance may decrease pressor responses to the vasoconstrictor endothelin 1. This study aimed to examine the effects of a NO synthesis inhibitor (NG‐nitro‐L‐arginine methyl ester; L‐NAME) on vascular responsiveness to endothelin 1 in normal and cirrhotic rats. Methods: Pressor dose‐response curves to endothelin 1 (0.5, 1, 3, 6, and 10 μg/kg intravenously) were obtained in animals with or without pretreatment with L‐NAME.

K. R. Reddy – 1 November 1995

David J. Bronster, Mika W. Lidov, David Wolfe, Myron E. Schwartz, Charles M. Miller – 1 November 1995 – Six weeks after liver transplantation, a 51‐year‐old man developed a slowly progressive hemiparesis with deteriorating mental status and seizures. Successive computed tomography (CT) scans of the brain revealed unilateral nonenhancing white matter lucencies that gradually coalesced and progressed to both hemispheres. Brain biopsy results were consistent with progressive multifocal leukoencephalopathy (PML).

Byers W Shaw – 1 November 1995